CINACALCET

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H22F3N
Molecular Weight	357.412
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](NCCCC1=CC(=CC=C1)C(F)(F)F)C2=CC=CC3=CC=CC=C23

InChI

InChIKey=VDHAWDNDOKGFTD-MRXNPFEDSA-N

InChI=1S/C22H22F3N/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3/t16-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H22F3N
Molecular Weight	357.412
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021688s20_21_22lbl.pdf

Cinacalcet is a positive allosteric modulator of calcium sensing receptor. The drug is approved by FDA (Sensipar trade name) and used for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; hypercalcemia in adult patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Calcium sensing receptor 10 Target ID: CHEMBL1878 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021688s20_21_22lbl.pdf	Positive Allosteric Modulator 179

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypercalcemia in patients with parathyroid carcinoma 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021688s20_21_22lbl.pdf	Primary		Approved 8429	SENSIPAR Approved Use Sensipar is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis; Hypercalcemia in adult patients with Parathyroid Carcinoma; Hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy. Launch Date 2004
Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021688s20_21_22lbl.pdf	Primary		Approved 8429	SENSIPAR Approved Use Sensipar is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis; Hypercalcemia in adult patients with Parathyroid Carcinoma; Hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy. Launch Date 2004

C_max

Value	Dose	Analyte	Population
29.9 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17515696	90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered:	CINACALCET blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
26.6 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15871636	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	CINACALCET plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
20.6 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15871636	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	CINACALCET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
323 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17515696	90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered:	CINACALCET blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
296 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15871636	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	CINACALCET plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
346 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15871636	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	CINACALCET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
12.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/17515696	90 mg single, oral dose: 90 mg route of administration: Oral experiment type: SINGLE co-administered:	CINACALCET blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
30.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15871636	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	CINACALCET plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
33.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/15871636	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	CINACALCET plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
100 mg single, oral Highest studied dose Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22503212	healthy, 20 - 35 years n = 6 Health Status: healthy Age Group: 20 - 35 years Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/22503212	Other AEs: Nasal congestion, Diarrhea... Other AEs: Nasal congestion (1 patient) Diarrhea (1 patient) Dyspepsia (3 patients) Peripheral sensory neuropathy (1 patient) Vomiting (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/22503212
300 mg 1 times / day multiple, oral Highest studied dose Dose: 300 mg, 1 times / day Route: oral Route: multiple Dose: 300 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21688_sensipar_lbl.pdf https://pubmed.ncbi.nlm.nih.gov/15558528	unhealthy, 49 years (range: 31-71 years) n = 7 Health Status: unhealthy Age Group: 49 years (range: 31-71 years) Sex: M+F Population Size: 7 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21688_sensipar_lbl.pdf https://pubmed.ncbi.nlm.nih.gov/15558528	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21688_sensipar_lbl.pdf https://pubmed.ncbi.nlm.nih.gov/15558528
180 mg 1 times / day steady, oral (max) Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00345839	unhealthy n = 1938 Health Status: unhealthy Condition: Secondary Hyperparathyroidism Population Size: 1938 Sources: https://clinicaltrials.gov/ct2/show/NCT00345839	Other AEs: Anaemia, Coagulopathy... Other AEs: Anaemia (serious, 42 patients) Coagulopathy (serious, 2 patients) Anaemia haemolytic (serious, 1 patient) Haemorrhagic anaemia (serious, 5 patients) Haemorrhagic disorder (serious, 1 patient) Leukocytosis (serious, 4 patients) Leukopenia (serious, 2 patients) Neutropenia (serious, 2 patients) Acute myocardial infarction (serious, 47 patients) Angina unstable (serious, 52 patients) Aortic valve stenosis (serious, 7 patients) Atrial flutter (serious, 12 patients) Atrial tachycardia (serious, 1 patient) Atrioventricular block (serious, 5 patients) Bradycardia (serious, 12 patients) Block bundle branch (serious, 1 patient) Cardiac arrest (serious, 60 patients) Cardiac failure acute (serious, 6 patients) Cardio-respiratory arrest (serious, 27 patients) Cardiogenic shock (serious, 12 patients) Cardiovascular disorder (serious, 1 patient) Coronary artery disease (serious, 28 patients) Coronary artery insufficiency (serious, 1 patient) Coronary artery stenosis (serious, 5 patients) Dilatation ventricular (serious, 1 patient) Left ventricular dysfunction (serious, 2 patients) Mitral valve calcification (serious, 1 patient) Mitral valve disease (serious, 2 patients) Myocardial infarction (serious, 109 patients) Myocardial ischaemia (serious, 11 patient) Palpitations (serious, 6 patients) Pericardial effusion (serious, 8 patients) Pericarditis (serious, 3 patients) Right ventricular failure (serious, 2 patients) Sinus tachycardia (serious, 2 patients) Supraventricular extrasystoles (serious, 1 patient) Ventricular tachyarrhythmia (serious, 1 patient) Ventricular tachycardia (serious, 12 patients) Adenomatous polyposis coli (serious, 1 patient) Congenital cystic kidney disease (serious, 6 patients) Gastrointestinal arteriovenous malformation (serious, 2 patients) Left ventricle outflow tract obstruction (serious, 1 patient) Meniere's disease (serious, 1 patient) Vertigo (serious, 4 patients) Vertigo positional (serious, 1 patient) Disorder vestibular (serious, 1 patient) Adrenal insufficiency (serious, 1 patient) Parathyroid gland enlargement (serious, 2 patients) Thyroid cyst (serious, 1 patient) Thyroiditis (serious, 1 patient) Age-related macular degeneration (serious, 1 patient) Cataract (serious, 8 patients) Cataract cortical (serious, 1 patient) Conjunctivitis (serious, 2 patients) Diabetic retinopathy (serious, 1 patient) Exophthalmos (serious, 1 patient) Eye haemorrhage (serious, 3 patients) Atrophy optic (serious, 1 patient) Retinal detachment (serious, 3 patients) Retinal vein thrombosis (serious, 1 patient) Hypertensive retinopathy (serious, 1 patient) Visual impairment (serious, 1 patient) Vitreous haemorrhage (serious, 2 patients) Abdominal distension (serious, 1 patient) Abdominal hernia obstructive (serious, 1 patient) Abdominal pain upper (serious, 5 patients) Abdominal rigidity (serious, 1 patient) Abdominal strangulated hernia (serious, 2 patients) Barrett's oesophagus (serious, 1 patient) Colitis ischaemic (serious, 9 patients) Constipation (serious, 8 patients) Diabetic gastroparesis (serious, 2 patients) Diarrhoea (serious, 32 patients) Dieulafoy's vascular malformation (serious, 1 patient) Diverticular perforation (serious, 2 patients) Diverticulum (serious, 1 patient) Duodenal ulcer (serious, 7 patients) Dyspepsia (serious, 3 patients) Dysphagia (serious, 3 patients) Enteritis (serious, 5 patients) Erosive oesophagitis (serious, 1 patient) Faecaloma (serious, 3 patients) Gastric hypermotility (serious, 1 patient) Gastric ulcer (serious, 12 patients) Gastric ulcer haemorrhage (serious, 2 patients) Gastritis haemorrhagic (serious, 1 patient) Gastroduodenitis (serious, 1 patient) Gastrointestinal angiodysplasia (serious, 2 patients) Gastrointestinal haemorrhage (serious, 54 patients) Gastrointestinal inflammation (serious, 2 patients) Gastrointestinal ulcer haemorrhage (serious, 1 patient) Gastrooesophageal reflux disease (serious, 4 patients) Haematemesis (serious, 5 patients) Haemorrhagic erosive gastritis (serious, 1 patient) Haemorrhoids (serious, 5 patients) Hernial eventration (serious, 1 patient) Hiatus hernia (serious, 2 patients) Ileus (serious, 6 patients) Impaired gastric emptying (serious, 6 patients) Intestinal haemorrhage (serious, 2 patients) Intestinal ischaemia (serious, 9 patients) Intestinal mass (serious, 1 patient) Intestinal obstruction (serious, 5 patients) Intestinal perforation (serious, 1 patient) Intestinal ulcer (serious, 1 patient) Irritable bowel syndrome (serious, 1 patient) Ischaemic gastritis (serious, 1 patient) Intestinal large ulcer (serious, 1 patient) Lumbar hernia (serious, 1 patient) Mechanical ileus (serious, 1 patient) Melaena (serious, 3 patients) Mesenteric artery stenosis (serious, 2 patients) Nausea (serious, 20 patients) Necrotising colitis (serious, 1 patient) Achalasia oesophageal (serious, 1 patient) Oesophageal food impaction (serious, 1 patient) Oesophageal perforation (serious, 1 patient) Oesophagitis (serious, 6 patients) Oesophagitis haemorrhagic (serious, 1 patient) Chronic pancreatitis (serious, 2 patients) Peptic ulcer haemorrhage (serious, 1 patient) Haemorrhage retroperitoneal (serious, 1 patient) Short-bowel syndrome (serious, 1 patient) Small intestinal obstruction (serious, 5 patients) Stomach mass (serious, 1 patient) Stress ulcer (serious, 1 patient) Subileus (serious, 1 patient) Tooth loss (serious, 1 patient) Tooth socket haemorrhage (serious, 1 patient) Upper gastrointestinal haemorrhage (serious, 11 patient) Vomiting (serious, 33 patients) Catheter site haematoma (serious, 3 patients) Catheter site pain (serious, 1 patient) Catheter site swelling (serious, 1 patient) Chest discomfort (serious, 4 patients) Chills (serious, 4 patients) Device dislocation (serious, 2 patients) Device occlusion (serious, 2 patients) Drug intolerance (serious, 1 patient) Drug withdrawal syndrome (serious, 1 patient) Fat necrosis (serious, 1 patient) Hernia (serious, 1 patient) Hernia pain (serious, 1 patient) Hyperthermia (serious, 2 patients) Implant site haematoma (serious, 1 patient) Influenza like illness (serious, 1 patient) Localised oedema (serious, 1 patient) Multi-organ failure (serious, 8 patients) Necrosis (serious, 1 patient) Non-cardiac chest pain (serious, 27 patients) Organ failure (serious, 1 patient) Pelvic mass (serious, 1 patient) Precancerous mucosal lesion (serious, 1 patient) Pyrexia (serious, 42 patients) Spinal pain (serious, 2 patients) Systemic inflammatory response syndrome (serious, 1 patient) Bile duct stone (serious, 3 patients) Cholangitis (serious, 3 patients) Cholangitis acute (serious, 1 patient) Cholecystitis acute (serious, 7 patients) Cholecystitis chronic (serious, 1 patient) Cholelithiasis (serious, 16 patients) Cholestasis (serious, 2 patients) Gallbladder polyp (serious, 2 patients) Hepatic function abnormal (serious, 1 patient) Hepatic lesion (serious, 1 patient) Amyloidosis (serious, 1 patient) Kidney transplant rejection (serious, 6 patients) Abdominal abscess (serious, 2 patients) Abdominal wall abscess (serious, 4 patients) Abscess (serious, 3 patients) Abscess limb (serious, 9 patients) Abscess neck (serious, 1 patient) Abscess of eyelid (serious, 1 patient) Abscess oral (serious, 1 patient) Acute sinusitis (serious, 1 patient) Appendicitis (serious, 6 patients) Appendicitis perforated (serious, 1 patient) Arteriosclerotic gangrene (serious, 1 patient) Arteriovenous graft site infection (serious, 25 patients) Arthritis bacterial (serious, 4 patients) Arthritis infective (serious, 2 patients) Bacteraemia (serious, 27 patients) Bacterial infection (serious, 1 patient) Biliary tract infection (serious, 1 patient) Bronchitis (serious, 26 patients) Catheter site cellulitis (serious, 2 patients) Cellulitis orbital (serious, 1 patient) Clostridial infection (serious, 3 patients) Clostridium colitis (serious, 1 patient) Clostridium difficile colitis (serious, 9 patients) Dengue fever (serious, 2 patients) Device related infection (serious, 29 patients) Diverticulitis (serious, 9 patients) Endocarditis (serious, 13 patients) Enteritis infectious (serious, 2 patients) Enterobacter bacteraemia (serious, 2 patients) Enterobacter pneumonia (serious, 1 patient) Enterobacter sepsis (serious, 3 patients) Enterococcal bacteraemia (serious, 3 patients) Enterococcal infection (serious, 1 patient) Enterocolitis infectious (serious, 2 patients) Escherichia bacteraemia (serious, 1 patient) Eye infection (serious, 2 patients) Fungal oesophagitis (serious, 1 patient) Gas gangrene (serious, 1 patient) Gastroenteritis (serious, 24 patients) Gastroenteritis viral (serious, 8 patients) Giardiasis (serious, 1 patient) H1N1 influenza (serious, 3 patients) Haematoma infection (serious, 2 patients) Haemophilus infection (serious, 2 patients) Helicobacter infection (serious, 1 patient) Hepatitis C (serious, 2 patients) Herpes zoster (serious, 4 patients) Implant site infection (serious, 1 patient) Infected fistula (serious, 3 patients) Infectious peritonitis (serious, 1 patient) Infective aneurysm (serious, 1 patient) Infective tenosynovitis (serious, 1 patient) Influenza (serious, 4 patients) Joint abscess (serious, 1 patient) Klebsiella bacteraemia (serious, 1 patient) Lower respiratory tract infection (serious, 11 patient) Lower respiratory tract infection bacterial (serious, 1 patient) Bacterial meningitis (serious, 1 patient) Cryptococcal meningitis (serious, 1 patient) Meningitis viral (serious, 1 patient) Nasal abscess (serious, 1 patient) Orchitis (serious, 1 patient) Periorbital cellulitis (serious, 1 patient) Perirectal abscess (serious, 2 patients) Peritoneal abscess (serious, 1 patient) Peritonitis (serious, 9 patients) Abscess peritonsillar (serious, 1 patient) Pilonidal cyst (serious, 1 patient) Pneumonia escherichia (serious, 1 patient) Pneumonia fungal (serious, 1 patient) Pneumonia primary atypical (serious, 2 patients) Pneumonia viral (serious, 2 patients) Post procedural infection (serious, 1 patient) Post procedural pneumonia (serious, 1 patient) Postoperative abscess (serious, 3 patients) Pseudomonas infection (serious, 1 patient) Pulmonary tuberculosis (serious, 1 patient) Pyelocystitis (serious, 1 patient) Pyelonephritis (serious, 9 patients) Pyelonephritis acute (serious, 2 patients) Rectal abscess (serious, 1 patient) Renal cyst infection (serious, 2 patients) Respiratory tract infection bacterial (serious, 1 patient) Respiratory tract infection viral (serious, 1 patient) Scrotal abscess (serious, 1 patient) Sepsis (serious, 123 patients) Serratia bacteraemia (serious, 1 patient) Staphylococcal bacteraemia (serious, 9 patients) Infection staphylococcal (serious, 14 patients) Staphylococcal osteomyelitis (serious, 2 patients) Staphylococcal sepsis (serious, 12 patients) Streptococcal sepsis (serious, 1 patient) Subcutaneous abscess (serious, 6 patients) Testicular abscess (serious, 1 patient) Tooth abscess (serious, 1 patient) Tooth infection (serious, 1 patient) Upper respiratory tract infection (serious, 7 patients) Vestibular neuronitis (serious, 1 patient) Viral infection (serious, 5 patients) Viral pharyngitis (serious, 1 patient) Wound infection bacterial (serious, 1 patient) Wound infection staphylococcal (serious, 2 patients) Zygomycosis (serious, 1 patient) Acetabulum fracture (serious, 2 patients) Animal bite (serious, 1 patient) Ankle fracture (serious, 9 patients) Arteriovenous fistula occlusion (serious, 13 patients) Arteriovenous fistula site haematoma (serious, 3 patients) Arteriovenous fistula thrombosis (serious, 49 patients) Arteriovenous graft aneurysm (serious, 2 patients) Arteriovenous graft site haemorrhage (serious, 9 patients) Brain herniation (serious, 1 patient) Complications of transplanted kidney (serious, 3 patients) Contusion (serious, 4 patients) Cystitis radiation (serious, 1 patient) Eye operation complication (serious, 1 patient) Face injury (serious, 1 patient) Forearm fracture (serious, 3 patients) Foreign body (serious, 1 patient) Fracture (serious, 3 patients) Fractured coccyx (serious, 1 patient) Graft complication (serious, 1 patient) Graft haemorrhage (serious, 1 patient) Graft thrombosis (serious, 7 patients) Haemodialysis-induced symptom (serious, 4 patients) In-stent coronary artery restenosis (serious, 2 patients) Joint dislocation (serious, 5 patients) Kidney rupture (serious, 1 patient) Overdose (serious, 6 patients) Pelvic fracture (serious, 3 patients) Pneumothorax traumatic (serious, 1 patient) Post procedural haemorrhage (serious, 5 patients) Postoperative adhesion (serious, 1 patient) Postoperative ileus (serious, 1 patient) Postoperative thoracic procedure complication (serious, 1 patient) Postoperative wound complication (serious, 2 patients) Procedural complication (serious, 1 patient) Procedural hypotension (serious, 10 patients) Shunt aneurysm (serious, 1 patient) Shunt occlusion (serious, 10 patients) Shunt stenosis (serious, 6 patients) Shunt thrombosis (serious, 8 patients) Spinal column injury (serious, 1 patient) Splenic rupture (serious, 1 patient) Subdural haematoma (serious, 8 patients) Suture rupture (serious, 1 patient) Transplant failure (serious, 3 patients) Vascular access complication (serious, 15 patients) Vascular graft complication (serious, 13 patients) Vascular graft occlusion (serious, 8 patients) Vascular pseudoaneurysm (serious, 8 patients) Wound dehiscence (serious, 4 patients) Blood calcium decreased (serious, 1 patient) Blood potassium increased (serious, 4 patients) Blood pressure increased (serious, 2 patients) C-reactive protein increased (serious, 2 patients) Cardioactive drug level increased (serious, 1 patient) Clostridium test positive (serious, 1 patient) Electrocardiogram ST segment abnormal (serious, 1 patient) Electrocardiogram ST-T segment abnormal (serious, 1 patient) Electrocardiogram abnormal (serious, 2 patients) Electrocardiogram change (serious, 3 patients) Fibrin D dimer increased (serious, 1 patient) Haematocrit decreased (serious, 1 patient) Haemoglobin decreased (serious, 6 patients) Heart rate irregular (serious, 1 patient) Influenza virus test positive (serious, 1 patient) International normalised ratio decreased (serious, 1 patient) International normalised ratio fluctuation (serious, 1 patient) International normalised ratio increased (serious, 2 patients) Liver function test abnormal (serious, 1 patient) Acidosis (serious, 3 patients) Cachexia (serious, 4 patients) Decreased appetite (serious, 3 patients) Dehydration (serious, 6 patients) Diabetic ketoacidosis (serious, 4 patients) Failure to thrive (serious, 6 patients) Hypercalcaemia (serious, 3 patients) Hyperkalaemia (serious, 97 patients) Hyperphosphataemia (serious, 1 patient) Hypocalcaemia (serious, 16 patients) Hypoglycaemia (serious, 34 patients) Hyponatraemia (serious, 1 patient) Lactic acidosis (serious, 1 patient) Malnutrition (serious, 2 patients) Hypoglycaemic shock (serious, 1 patient) Type 1 diabetes mellitus (serious, 1 patient) Arthralgia (serious, 11 patient) Cervical spinal stenosis (serious, 2 patients) Chondrocalcinosis pyrophosphate (serious, 1 patient) Costochondritis (serious, 2 patients) Intervertebral disc degeneration (serious, 1 patient) Intervertebral disc disorder (serious, 2 patients) Intervertebral disc protrusion (serious, 6 patients) Destruction joint (serious, 1 patient) Limb deformity (serious, 1 patient) Mobility decreased (serious, 1 patient) Muscular weakness (serious, 9 patients) Musculoskeletal disorder (serious, 1 patient) Musculoskeletal stiffness (serious, 1 patient) Neuropathic arthropathy (serious, 1 patient) Osteonecrosis (serious, 4 patients) Osteopenia (serious, 1 patient) Pain in extremity (serious, 13 patients) Periarthritis (serious, 1 patient) Pseudarthrosis (serious, 1 patient) Arthropathy psoriatic (serious, 1 patient) Rotator cuff syndrome (serious, 2 patients) Scleroderma (serious, 1 patient) Spinal column stenosis (serious, 1 patient) Spondylolisthesis (serious, 1 patient) Acute myeloid leukaemia (serious, 1 patient) Adenocarcinoma (serious, 1 patient) Adenoma benign (serious, 1 patient) B-cell lymphoma (serious, 1 patient) Bladder cancer (serious, 4 patients) Bladder cancer recurrent (serious, 1 patient) Bladder neoplasm (serious, 3 patients) Brain cancer metastatic (serious, 1 patient) Brain neoplasm (serious, 1 patient) Breast cancer (serious, 7 patients) Breast cancer metastatic (serious, 2 patients) Chronic lymphocytic leukaemia (serious, 1 patient) Chronic myeloid leukaemia (serious, 1 patient) Colon neoplasm (serious, 1 patient) Hepatic neoplasm malignant (serious, 1 patient) Intraocular melanoma (serious, 1 patient) Lentigo maligna stage unspecified (serious, 1 patient) Adenocarcinoma lung (serious, 2 patients) Lung neoplasm malignant (serious, 4 patients) Lymphoma (serious, 1 patient) Malignant melanoma (serious, 2 patients) Malignant pleural effusion (serious, 1 patient) Malignant urinary tract neoplasm (serious, 1 patient) Metastases to central nervous system (serious, 1 patient) Metastases to lung (serious, 1 patient) Metastases to peritoneum (serious, 1 patient) Metastatic malignant melanoma (serious, 1 patient) Metastatic neoplasm (serious, 4 patients) Neoplasm malignant (serious, 1 patient) Neoplasm skin (serious, 2 patients) Non-Hodgkin's lymphoma (serious, 1 patient) Pancreatic carcinoma (serious, 2 patients) Prostate cancer (serious, 8 patients) Prostate cancer metastatic (serious, 1 patient) Renal cell carcinoma (serious, 6 patients) Renal oncocytoma (serious, 1 patient) Small cell lung cancer stage unspecified (serious, 1 patient) Neoplasm thyroid (serious, 3 patients) Transitional cell carcinoma (serious, 1 patient) Tumour haemorrhage (serious, 1 patient) Vaginal cancer (serious, 1 patient) Aphasia (serious, 1 patient) Autonomic neuropathy (serious, 2 patients) Balance disorder (serious, 3 patients) Basal ganglia haemorrhage (serious, 1 patient) Brain stem infarction (serious, 1 patient) Cerebral atrophy (serious, 1 patient) Cerebral haemorrhage (serious, 10 patients) Cerebral infarction (serious, 5 patients) Clonus (serious, 1 patient) Coma (serious, 3 patients) Convulsion (serious, 30 patients) Dizziness (serious, 9 patients) Dyskinesia (serious, 1 patient) Encephalitis (serious, 1 patient) Encephalitis post varicella (serious, 1 patient) Encephalomalacia (serious, 1 patient) Epilepsy (serious, 3 patients) Extrapyramidal disorder (serious, 2 patients) Guillain Barre syndrome (serious, 1 patient) Haemorrhage intracranial (serious, 7 patients) Headache (serious, 6 patients) Hemianopia (serious, 1 patient) Hypogeusia (serious, 1 patient) Hypoglycaemic encephalopathy (serious, 1 patient) Hypotonia (serious, 1 patient) Hypoxic-ischaemic encephalopathy (serious, 4 patients) Ischaemic stroke (serious, 8 patients) Migraine (serious, 2 patients) Myelitis transverse (serious, 1 patient) Nerve compression (serious, 2 patients) Neuralgia (serious, 1 patient) Optic neuritis (serious, 1 patient) Paraesthesia (serious, 2 patients) Partial seizures (serious, 1 patient) Post herpetic neuralgia (serious, 1 patient) Presyncope (serious, 3 patients) Somnolence (serious, 2 patients) Status epilepticus (serious, 3 patients) Stupor (serious, 1 patient) Haemorrhage subarachnoid (serious, 5 patients) Transient ischaemic attack (serious, 15 patients) Tremor (serious, 2 patients) Uraemic encephalopathy (serious, 2 patients) Uraemic neuropathy (serious, 1 patient) Dementia vascular (serious, 2 patients) Bipolar disorder (serious, 1 patient) Confusional state (serious, 8 patients) Conversion disorder (serious, 1 patient) Disorientation (serious, 2 patients) Drug abuse (serious, 2 patients) Hallucination (serious, 1 patient) Major depression (serious, 2 patients) Psychotic disorder (serious, 2 patients) Restlessness (serious, 1 patient) Schizophrenia (serious, 1 patient) Substance abuse (serious, 1 patient) Suicidal ideation (serious, 2 patients) Calculus ureteric (serious, 1 patient) Cystitis haemorrhagic (serious, 2 patients) Nephrolithiasis (serious, 2 patients) Colic renal (serious, 2 patients) Renal cyst haemorrhage (serious, 1 patient) Renal haemorrhage (serious, 4 patients) Renal injury (serious, 1 patient) Renal tubular necrosis (serious, 2 patients) Urethral prolapse (serious, 1 patient) Urethral stenosis (serious, 2 patients) Haemorrhage urinary bladder (serious, 1 patient) Breast inflammation (serious, 1 patient) Epididymitis (serious, 1 patient) Female genital tract fistula (serious, 1 patient) Disease fibrocystic breast (serious, 1 patient) Menometrorrhagia (serious, 1 patient) Menorrhagia (serious, 1 patient) Pelvic adhesions (serious, 1 patient) Priapism (serious, 1 patient) Scrotal haematocoele (serious, 1 patient) Scrotal pain (serious, 1 patient) Scrotal swelling (serious, 1 patient) Testicular haemorrhage (serious, 1 patient) Uterine polyp (serious, 2 patients) Vaginal laceration (serious, 1 patient) Prolapse vaginal (serious, 1 patient) Atelectasis (serious, 4 patients) Chronic obstructive pulmonary disease (serious, 20 patients) Dyspnoea (serious, 47 patients) Dyspnoea exertional (serious, 1 patient) Epistaxis (serious, 10 patients) Haemothorax (serious, 3 patients) Hypercapnia (serious, 2 patients) Hypoventilation (serious, 1 patient) Interstitial lung disease (serious, 3 patients) Laryngeal cyst (serious, 1 patient) Lung consolidation (serious, 2 patients) Lung infiltration (serious, 2 patients) Nasal septum deviation (serious, 1 patient) Pleural disorder (serious, 1 patient) Pleural effusion (serious, 32 patients) Aspiration pneumonia (serious, 4 patients) Pneumonitis (serious, 5 patients) Pulmonary alveolar haemorrhage (serious, 1 patient) Pulmonary arterial hypertension (serious, 1 patient) Pulmonary fibrosis (serious, 1 patient) Pulmonary necrosis (serious, 1 patient) Respiratory arrest (serious, 8 patients) Respiratory disorder (serious, 1 patient) Respiratory distress (serious, 5 patients) Status asthmaticus (serious, 1 patient) Stridor (serious, 1 patient) Tachypnoea (serious, 1 patient) Vocal cord polyp (serious, 1 patient) Angioedema (serious, 3 patients) Dermal cyst (serious, 2 patients) Dermatitis acneiform (serious, 1 patient) Diabetic foot (serious, 9 patients) Erythema nodosum (serious, 1 patient) Abnormal hair growth (serious, 1 patient) Hidradenitis (serious, 1 patient) Hyperkeratosis (serious, 1 patient) Necrosis skin (serious, 4 patients) Subcutaneous emphysema (serious, 1 patient) Activities of daily living impaired (serious, 1 patient) Treatment noncompliance (serious, 1 patient) Incisional drainage (serious, 1 patient) Therapy cessation (serious, 5 patients) Aneurysm (serious, 1 patient) Angiopathy (serious, 1 patient) Aortic aneurysm rupture (serious, 2 patients) Arterial haemorrhage (serious, 1 patient) Arterial insufficiency (serious, 1 patient) Arterial stenosis (serious, 3 patients) Arteritis (serious, 5 patients) Deep vein thrombosis (serious, 10 patients) Diabetic macroangiopathy (serious, 1 patient) Diabetic vascular disorder (serious, 3 patients) Femoral arterial stenosis (serious, 8 patients) Femoral artery occlusion (serious, 1 patient) Haemorrhage (serious, 5 patients) Hypertension (serious, 49 patients) Hypertensive crisis (serious, 29 patients) Hypertensive emergency (serious, 12 patients) Hypotension (serious, 54 patients) Iliac artery occlusion (serious, 1 patient) Iliac artery stenosis (serious, 4 patients) Intra-abdominal haematoma (serious, 2 patients) Ischaemic limb pain (serious, 2 patients) Hypertension malignant (serious, 6 patients) Orthostatic hypotension (serious, 5 patients) Peripheral arterial occlusive disease (serious, 13 patients) Peripheral artery aneurysm (serious, 1 patient) Disorder peripheral vascular (serious, 30 patients) Phlebitis (serious, 2 patients) Steal syndrome (serious, 7 patients) Subclavian artery aneurysm (serious, 1 patient) Subclavian artery stenosis (serious, 1 patient) Superior vena cava syndrome (serious, 7 patients) Systolic hypertension (serious, 1 patient) Superficial thrombophlebitis (serious, 1 patient) Thrombosis (serious, 4 patients) Varicose ulceration (serious, 2 patients) Vascular calcification (serious, 2 patients) Vascular occlusion (serious, 1 patient) Vena cava thrombosis (serious, 1 patient) Venous aneurysm (serious, 1 patient) Venous occlusion (serious, 4 patients) Venous stenosis (serious, 9 patients) Anaemia (below serious, 109 patients) Abdominal pain (below serious, 187 patients) Abdominal pain upper (below serious, 153 patients) Diarrhoea (below serious, 376 patients) Dyspepsia (below serious, 140 patients) Nausea (below serious, 552 patients) Vomiting (below serious, 482 patients) Chest pain (below serious, 134 patients) Oedema peripheral (below serious, 117 patients) Bronchitis (below serious, 138 patients) Nasopharyngitis (below serious, 157 patients) Upper respiratory tract infection (below serious, 144 patients) Urinary tract infection (below serious, 114 patients) Arteriovenous fistula site complication (below serious, 124 patients) Decreased appetite (below serious, 112 patients) Hypocalcaemia (below serious, 206 patients) Back pain (below serious, 159 patients) Muscle spasms (below serious, 213 patients) Pain in extremity (below serious, 201 patient) Dizziness (below serious, 135 patients) Headache (below serious, 219 patients) Cough (below serious, 225 patients) Dyspnoea (below serious, 226 patients) Hypertension (below serious, 176 patients) Hypotension (below serious, 183 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00345839
180 mg 1 times / day steady, oral (max) Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00975000	unhealthy n = 57 Health Status: unhealthy Condition: Hyperparathyroidism Population Size: 57 Sources: https://clinicaltrials.gov/ct2/show/NCT00975000	Other AEs: Anaemia, Glaucoma... Other AEs: Anaemia (serious, 1 patient) Glaucoma (serious, 1 patient) Abdominal hernia (serious, 1 patient) Abdominal pain upper (serious, 1 patient) Diarrhoea (serious, 1 patient) Hernia inguinal (serious, 1 patient) Pancreatitis acute (serious, 1 patient) Influenza like illness (serious, 1 patient) Kidney transplant rejection (serious, 1 patient) Cystitis (serious, 1 patient) Cytomegalovirus infection (serious, 2 patients) Gastroenteritis viral (serious, 1 patient) Lung infection (serious, 1 patient) Pneumonia (serious, 1 patient) Foot fracture (serious, 1 patient) Lung adenocarcinoma metastatic (serious, 1 patient) Cerebrovascular accident (serious, 1 patient) Renal impairment (serious, 1 patient) Lung infiltration (serious, 1 patient) Abdominal discomfort (below serious, 3 patients) Diarrhoea (below serious, 8 patients) Nausea (below serious, 7 patients) Malaise (below serious, 4 patients) Upper respiratory tract infection (below serious, 5 patients) Urinary tract infection (below serious, 8 patients) Gout (below serious, 3 patients) Hypercholesterolaemia (below serious, 4 patients) Hyperlipidaemia (below serious, 3 patients) Hypokalaemia (below serious, 4 patients) Hypomagnesaemia (below serious, 5 patients) Arthralgia (below serious, 3 patients) Back pain (below serious, 5 patients) Headache (below serious, 5 patients) Insomnia (below serious, 3 patients) Cough (below serious, 8 patients) Oropharyngeal pain (below serious, 3 patients) Hypertension (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00975000

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037 inducer 389 inhibitor 1767	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
L-type Ca2+ 2 CYP1A2 1524 CYP2C19 1478	CYP1A2 1054 CYP2C19 991 CYP2A6 543 CYP2E1 667

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021688s027lbl.pdf#page=12 Page: 12.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021688s027lbl.pdf#page=12 Page: 12.0	no
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_BioPharmr.pdf#page=33 Page: 33.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021688s027lbl.pdf#page=12 Page: 12.0	no
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021688s027lbl.pdf#page=12 Page: 12.0	no
L-type Ca2+ 7	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Pharmr_P1.pdf#page=24 Page: 24.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_BioPharmr.pdf#page=16 Page: 16,32	strong [IC50 0.07 uM]	yes (co-administration study) Comment: amitriptyline AUC(0-inf) with coadministration of cinacalcet were within that upon coadministration of placebo Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_BioPharmr.pdf#page=16 Page: 16,32

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2C19 991	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_BioPharmr.pdf#page=15 Page: 15.0	likely
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Pharmr_P1.pdf#page=34 Page: 34.0	likely
CYP2D6 1217	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_BioPharmr.pdf#page=15 Page: 15.0	likely
CYP1A2 1054	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Pharmr_P1.pdf#page=34 Page: 34.0	major
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Pharmr_P1.pdf#page=34 Page: 34.0	major	yes (co-administration study) Comment: adminstration with ketoconazole caused an approximate 2-fold increase in cinacalcet exposure; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Pharmr_P1.pdf#page=34 Page: 34.0
CYP2A6 543	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Pharmr_P1.pdf#page=34 Page: 34.0	no
CYP2E1 667	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Pharmr_P1.pdf#page=34 Page: 34.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-688.pdf_Sensipar_Pharmr_P1.pdf#page=24 Page: 5,24

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:48390	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:48390
ChemicalBook	CB5506688	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5506688
MolPort	MolPort-003-845-954	https://www.molport.com/shop/molecule-link/MolPort-003-845-954
ZINC	ZINC000001550499	http://zinc15.docking.org/substances/ZINC000001550499
eMolecules	31592306	https://www.emolecules.com/cgi-bin/more?vid=31592306

PubMed

Title	Date	PubMed
Secondary hyperparathyroidism: review of the disease and its treatment.	2004 Dec	15823762
Summary--calcium receptors: potential targets for novel treatments for skeletal disease.	2004 Dec	15758288
Clinical effects of calcimimetics in hyperparathyroidism.	2004 Dec	15758287
[New aspects in the management of renal osteodystrophy].	2004 Oct	15669206
New agents for the treatment of renal osteodystrophy.	2004 Oct-Dec	15673151
[New therapeutic strategies in secondary hyperparathyroidism on dialysis (II): vitamin D analogues and calcium-mimetics].	2005	16050413
Management of renal osteodystrophy in children.	2005	15884662
No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar/Mimpara).	2005	15871636
New prospects for the management of renal bone disease.	2005	15637457
Cinacalcet hydrochloride (Sensipar).	2005 Apr	16200170
The latest findings in basic and clinical nephrology science.	2005 Apr	15915223
Management of secondary hyperparathyroidism.	2005 Aug	16109140
Therapeutic failure of cinacalcet in a renal transplant patient presenting hyperparathyroidism with severe hypercalcaemia.	2005 Dec	16115841
Challenges in the therapy of secondary hyperparathyroidism.	2005 Feb	15828898
New drugs 05, part I.	2005 Feb	15706282
Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.	2005 Feb	15673327
Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.	2005 Feb	15673294
Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl.	2005 Jan	15864123
[Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].	2005 Jan	15632475
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis.	2005 Jul	15983958
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease.	2005 Jul	15954947
The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.	2005 Jul	15941846
Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.	2005 Jul	15941845
Calcimimetics: a remedy for all problems of excess parathyroid hormone activity in chronic kidney disease?	2005 Jul	15931004
1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.	2005 Jul	15855208
Cinacalcet cost and utility in dialysis patients.	2005 Jul-Aug	16076364
Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.	2005 Jun	15882311
Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.	2005 Jun	15840675
Calcimimetics and calcilytics--fooling the calcium receptor.	2005 Jun 25-Jul 1	15978932
Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.	2005 Mar	15794735
Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.	2005 Mar	15781990
Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.	2005 Mar	15689407
Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means.	2005 Mar	15662538
The role of cinacalcet in treating secondary hyperparathyroidism.	2005 Mar-Apr	15889812
[Calcimimetics--a new treatment for hyperparathyroidism?].	2005 May	16161961
Cinacalcet: a new treatment for secondary hyperparathyroidism in patients receiving hemodialysis.	2005 May	15899733
High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism.	2005 May	15840060
How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?	2005 May-Jun	15934970
[Chronic kidney disease].	2005 Nov 15	16328179
Gateways to clinical trials.	2005 Oct	16273137
Parathyroidectomy in the calcimimetic era.	2005 Oct	16221104
Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.	2005 Oct	16189180
Immunosuppressive and calcimimetic drug-drug interactions.	2005 Oct	16164678
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.	2005 Oct	16164656
Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.	2005 Oct	16030053
[Management of secondary hyperparathyroidism].	2005 Sep	16279027
First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.	2005 Sep	16105056
Cinacalcet and vascular calcifications induced by calcitriol.	2006 Feb	16221695
Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1.	2006 Jan	16291838
Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.	2006 Mar	16102839

Patents

Sample Use Guides

In Vivo Use Guide

Secondary HPT in patients with CKD on dialysis: starting dose is 30 mg once daily. Hypercalcemia: starting dose is 30 mg twice daily.

Route of Administration: Oral

In Vitro Use Guide

Cinacalcet (100 nM) suppressed parathyroid hormone secretion in human parathyroid cells.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:45:21 GMT 2023` Edited by `admin` on `Fri Dec 15 15:45:21 GMT 2023`
Record UNII	UAZ6V7728S
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CINACALCET

Official Name

English

AMG-073

Code

English

Cinacalcet [WHO-DD]

Common Name

English

CINACALCET [HSDB]

Common Name

English

1-NAPHTHALENEMETHANAMINE, .ALPHA.-METHYL-N-(3-(3-(TRIFLUOROMETHYL)PHENYL)PROPYL)-, (.ALPHA.R)-

Common Name

English

CINACALCET [EMA EPAR]

Common Name

English

KRN1493

Code

English

CINACALCET [MI]

Common Name

English

AMG073

Code

English

CINACALCET [USAN]

Common Name

English

N-[(1R)-1-(Naphthalen-1-yl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine

Systematic Name

English

CINACALCET [VANDF]

Common Name

English

AMG 073

Code

English

KRN-1493

Code

English

cinacalcet [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2136